2010 Commercial center Course of events for Nonexclusive Medications

Presentation Transcript

2010 Marketplace Timeline for Generic Drugs ANDRODERM androgen substitution EFFEXOR XR discouragement ASTELIN hypersensitivities COZAAR/HYZAAR pulse FEMARA (4Q2010 or 1Q2011) bosom growth DIASTAT (approved non specific) nervousness FEMHRT menopause side effects FLOMAX BPH AMERGE headache DIFFERIN skin inflammation ARIMIDEX prostate disease ARICEPT Alzheimer's Jul 10 Oct 10 Nov 10 Nov 10 Dec 10 Apr 10 May 10 May 10 Jun 10 Sep 10 Oct 10 Mar 10 VOLTAREN GEL joint inflammation KADIAN torment Generic Exclusivity Expected Expect 10-20% value lessening Expected Launch Possible Launch Launched Multiple Generic Manufacturers Expect 50-80% value diminishment

2011 Marketplace Timeline for Generic Drugs LIPITOR cholesterol RYTHMOL SR arrhythmias NASACORT AQ sensitivities ZYPREXA antipsychotic LOTREL (addt'l qualities) circulatory strain LEVAQUIN anti-microbial CADUET cholesterol/circulatory strain XALATAN glaucoma FEMCON FE anti-conception medication Jan 11 Mar 11 Mar 11 Jun 11 Jun 11 Nov11 Oct 11 PATANOL & PATANASE hypersensitivities TRICOR 48 mg & 145 mg cholesterol Generic Exclusivity Expected Expect 10-20% value decrease Expected Launch Possible Launch Launched Multiple Generic Manufacturers Expect 50-80% value lessening

2012 Anticipated Generics Plavix ® ( clopidogrel ) Atacand ® ( candesartan ) Actos ® ( pioglitazone ) Diovan ® and blends ( valsartan ) Geodon ® ( ziprasidone ) Singulair ® ( montelukast ) Clarinex ® ( desloratidine ) Avandia ® and mixes (rosiglitazone) Lexapro ® (escitalopram) Viagra ®/Revatio ® (sildenafil) Avapro ® (irbesartan) Seroquel ® (quetiapine) Provigil ® (modafinil)